References
1. Dedov I.I., Shestakova M.V., Vikulova O.K. National register of diabetes mellitus in Russian Federation: status on 2014. Sakharnyy diabet [Diabetes Mellitus]. 2015; 18 (3): 5-23. (in Russian)
2. Callaghan B.C., Little A.A., Feldman E.L., et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6: CD007543.
3. Han Y., Wang M., Shen J., et al. Differential efficacy of methylco-balamin and alpha-lipoic acid treatment on negative and positive symptoms of (type 2) diabetic peripheral neuropathy. Minerva Endocrinol. 2016 Nov. http://www.minervamedica.it/en/journals/minerva-endocrinologica/ article.php? cod =R07Y9999N00A16113001
4. Strokov I.A., Zakharov V.V., Strokov K.I. Diabetic encephalopathy. In: Diabetes mellitus type 2. Problems and solutions. 2nd edition, revised and expanded. Moscow: GEOTAR-Media, 2013: 647-69. (in Russian)
5. Bregovskiy V.B., Khramilin V.N., Demidova I.Yu., Strokov I.A., et al. Distal diabetic neuropathy: review of evidence-based recommendations. Annaly klinicheskoy i eksperimental’noy nevrologii [Annals of Clinical and Experimental Neurology]. 2015; 9 (1): 60-8. (in Russian)
6. Fokina A.S., Strokov I.A., Zilov A.V., Strokov K.I. The algorithm for personalized treatment of distal symmetrical sensory-motor polyneuropathy in patients with diabetes mellitus type 2. Effektivnaya farmakoterapiya. Endokrinologiya [Effective pharmacotherapy Endocrinology]. 2017; (2): 30-8. (in Russian)
7. Tesfaye S., Boulton A.J.M., Dyck P.J., Freeman R., et al.; on behalf of the Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010; 33 (10): 2285-93. doi: 10.2337/dc10-1303
8. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism // Diabetes. 2005; 54: 1615-25.
9. Callaghan B.C., Cheng H.T., Stables C.L., et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012; 11 (6): 521-34.
10. Ametov A.S., Barinov A.N., Dyck P.J., et al. The sensory symptoms of diabetic polyneuropathy are improved with a-lipoic acid. Diabetes Care. 2003; 26 (3): 770-6.
11. Ziegler D., Nowak H., Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant a-lipoic acid: a meta-analysis. Diabet Med. 2004; 21: 114-21.
12. Ziegler D., Ametov A., Barinov A., et al. Oral treatment with a-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006; 29: 2365-70.
13. Stracke H., Gaus W., Achenbach U., et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes. 2008; 116: 1-6.
14. Ziegler D., Movsesyan L., Mankovsky B., et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009; 32 (8): 1479-84.
15. Strokov I.A., Fokina F.S., Zilov F.V. Actovegin in treatment of neurological complications in diabetes mellitus. Effektivnaya farmakoterapiya. Endokrinologiya [Effective pharmacotherapy Endocrinology]. 2015; (43; 5): 20-7. (in Russian)
16. Sima A.A. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs. 2007; 21 (Suppl 1): 13-23.
17. Strokov I.A., Fokina A.S. a-Lipoic acid as the main pharmacological drug for in- and outpatient treatment of diabetic polyneuropathy. Meditsinskiy Sovet [Medical Council]. 2016; (17): 28-33. (in Russian)
18. Zhao L., Hu F.X. a-Lipoic acid treatment of aged type 2 diabetes mellitus complicated with acute cerebral infarction. Eur Rev Med Pharmacol Sci. 2014; 18 (23): 3715-9.
19. Fardieva R.M., Zalyuletdinova L.N., Gaynetdinova A.N. Study of the influence lipoic acid on intellectual-mental brain function of volunteers. Fundamental’nye issledovaniya [Fundamental Research]. 2013; (2; Ch. 1): 186-8. (in Russian)
20. Sosina V.B., Zakharov V.V., Strokov I.A., Vakhnina N.V. Cognitive impairment in diabetes mellitus. Nevrologiya, neiropsikhiatriya, psikho-somatika [Neurology, Neuropsychiatry, Psychosomatics]. 2017; 9 (1): 90-5. doi: http://dx.doi.org/10.14412/2074-2711-2017-1-90-95. (in Russian)
21. Strokov I.A., Zakharov V.V., Golovacheva V.A., Brand P.Ya. The activation of the cholinergic innervation in the treatment of diseases of the peripheral and central nervous system. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [S.S. Korsakov Journal of Neurology and Psychiatry]. 2013; 113 (6): 91-8. (in Russian)
22. Strokov I.A., Zinov’eva O.E., Barinov A.N., Akhmedzhanova L.T. Neuromidin administration in the course of treatment of diabetic polyneuropathy. Nevrologicheskiy zhurnal [The Neurological Journal]. 2007; 12 (6): 52-5. (in Russian)
23. Shah A.D., Langenberg C., Rapsomaniki E., et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015; 3 (2): 105-13.
24. Riksen N.P., Task C.J. The cardiovascular effects of metformin: lost in translation? Curr Opin Lipidol. 2014; 25 (6): 446-51.
25. El Messaoudi S., Russel F.G., Colbers A., et al. The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers. Eur J Clin Pharmacol. 2016; 72: 725-30.